Clinical Trials Logo

Clinical Trial Summary

The IHU Mediterranean infection is national reference centre for Q fever. Coxiella burnetii is the bacteria responsible of this infection. The bacterium Coxiella burnetii infection is associated with secretion by the body both many antibodies against the bacteria but also against certain cells of the body (autoantibodies). These autoantibodies may have no effect or be associated with specific symptoms. Anti-Phospholipid antibodies are especially prevalent in the Q fever. Apart from this infection, they are associated with thrombocytopenia, obstetric complications, thrombosis and heart valve damage. These conditions have also been described as complications during Q fever. In a retrospective preliminary work on Q fever, we have shown that the presence of high levels of IgG anti-cardiolipin was associated with the presence of valvular and the evolution to endocarditis. Such associations have a therapeutic involvement and must therefore be confirmed. Indeed, if these associations were confirmed, a trans-esophageal ultrasound could be systematically proposed to patients with valvular disease of trans-thoracique ultrasound but IgG anticardiolipin high levels. Other special attention could be given to patients with high autoantibodies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02822807
Study type Interventional
Source Assistance Publique Hopitaux De Marseille
Contact
Status Completed
Phase N/A
Start date July 2013
Completion date January 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03334019 - Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France
Active, not recruiting NCT01450501 - Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study) N/A
Recruiting NCT01095328 - A Screening Strategy for Q Fever Among Pregnant Women N/A
Completed NCT02898402 - Study on Seroprevalence and Risk Factors of Coxiella Burnetii (Q Fever) in the South of Reunion Island N/A
Completed NCT00584454 - Safety Evaluation of a Q-fever Vaccine, NDBR 105 Phase 2
Withdrawn NCT02092142 - Safety and Immunogenicity of Q Fever Vaccine Phase 2
Completed NCT01318356 - The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Phase 4